Marinus Pharmaceuticals Stock Fundamentals
| MRNS Stock | USD 0.33 0.01 3.13% |
Marinus Pharmaceuticals fundamentals help investors to digest information that contributes to Marinus Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Marinus Stock. The fundamental analysis module provides a way to measure Marinus Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Marinus Pharmaceuticals stock.
At this time, Marinus Pharmaceuticals' Interest Income is comparatively stable compared to the past year. Marinus | Select Account or Indicator |
Marinus Pharmaceuticals Company Return On Asset Analysis
Marinus Pharmaceuticals' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Marinus Pharmaceuticals Return On Asset | -0.58 |
Most of Marinus Pharmaceuticals' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Marinus Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Marinus Total Assets
Total Assets |
|
Based on the latest financial disclosure, Marinus Pharmaceuticals has a Return On Asset of -0.5775. This is 93.4% lower than that of the Pharmaceuticals sector and 97.55% lower than that of the Health Care industry. The return on asset for all United States stocks is notably higher than that of the company.
Marinus Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Marinus Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Marinus Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Marinus Pharmaceuticals competition to find correlations between indicators driving Marinus Pharmaceuticals's intrinsic value. More Info.Marinus Pharmaceuticals is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, Marinus Pharmaceuticals' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Marinus Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Marinus Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Marinus Pharmaceuticals' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Marinus Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Marinus Pharmaceuticals by comparing valuation metrics of similar companies.Marinus Pharmaceuticals is currently under evaluation in return on asset category among its peers.
Marinus Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Marinus Pharmaceuticals from analyzing Marinus Pharmaceuticals' financial statements. These drivers represent accounts that assess Marinus Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Marinus Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 117.4M | 117.7M | 436.0M | 155.5M | 584.2M | 613.4M | |
| Enterprise Value | 49.6M | 27.3M | 353.8M | (12.4M) | 574.0M | 602.7M |
Marinus Fundamentals
| Return On Equity | -29.87 | ||||
| Return On Asset | -0.58 | ||||
| Operating Margin | (3.76) % | ||||
| Current Valuation | 31.74 M | ||||
| Shares Outstanding | 55.19 M | ||||
| Shares Owned By Insiders | 10.94 % | ||||
| Shares Owned By Institutions | 83.03 % | ||||
| Number Of Shares Shorted | 5.66 M | ||||
| Price To Earning | (4.80) X | ||||
| Price To Book | 3.17 X | ||||
| Price To Sales | 0.59 X | ||||
| Revenue | 30.99 M | ||||
| Gross Profit | (55.94 M) | ||||
| EBITDA | (125.5 M) | ||||
| Net Income | (141.41 M) | ||||
| Cash And Equivalents | 168.25 M | ||||
| Cash Per Share | 4.52 X | ||||
| Total Debt | 110.36 M | ||||
| Debt To Equity | 0.88 % | ||||
| Current Ratio | 8.41 X | ||||
| Book Value Per Share | 0.31 X | ||||
| Cash Flow From Operations | (118 M) | ||||
| Short Ratio | 1.09 X | ||||
| Earnings Per Share | (2.47) X | ||||
| Target Price | 1.47 | ||||
| Number Of Employees | 165 | ||||
| Beta | 1.26 | ||||
| Market Capitalization | 17.94 M | ||||
| Total Asset | 170.91 M | ||||
| Retained Earnings | (571.93 M) | ||||
| Working Capital | 124.62 M | ||||
| Current Asset | 57.77 M | ||||
| Current Liabilities | 7.43 M | ||||
| Net Asset | 170.91 M |
About Marinus Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Marinus Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Marinus Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Marinus Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 18 M | 18.9 M | |
| Total Revenue | 31 M | 32.5 M | |
| Cost Of Revenue | 1.9 M | 1.8 M | |
| Stock Based Compensation To Revenue | 0.50 | 0.48 | |
| Sales General And Administrative To Revenue | 2.79 | 2.65 | |
| Research And Ddevelopement To Revenue | 3.21 | 3.05 | |
| Revenue Per Share | 0.58 | 0.61 | |
| Ebit Per Revenue | (4.24) | (4.46) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Marinus Stock Analysis
When running Marinus Pharmaceuticals' price analysis, check to measure Marinus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marinus Pharmaceuticals is operating at the current time. Most of Marinus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Marinus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marinus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Marinus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.